Cargando…
Osteonecrosis of the Jaw among Patients Receiving Antiresorptive Medication: A 4-year Retrospective Study at a Tertiary Cancer Center, Kerala, India
PURPOSE: Osteonecrosis of the jaw (ONJ) is a rare but complicated side effect of antiresorptive medications. The aim of the study is to evaluate the dental and drug-related factors related to ONJ among patients on these drugs at a tertiary cancer center, India. METHODOLOGY: A retrospective record re...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications & Media Pvt Ltd
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5863406/ https://www.ncbi.nlm.nih.gov/pubmed/29599581 http://dx.doi.org/10.4103/ccd.ccd_696_17 |
_version_ | 1783308382215602176 |
---|---|
author | Sankar, Pramod S Thilak, SA Nayak, P Tripathy, JP Satheesan, B Rajitha, AV |
author_facet | Sankar, Pramod S Thilak, SA Nayak, P Tripathy, JP Satheesan, B Rajitha, AV |
author_sort | Sankar, Pramod S |
collection | PubMed |
description | PURPOSE: Osteonecrosis of the jaw (ONJ) is a rare but complicated side effect of antiresorptive medications. The aim of the study is to evaluate the dental and drug-related factors related to ONJ among patients on these drugs at a tertiary cancer center, India. METHODOLOGY: A retrospective record review of patients who received antiresorptive medication at our center from 2011 to 2014 was done. The demographic factors, type, dosage, and duration of the medication and dental history were collected, and the data were entered an analyzed using Epidata software. RESULTS: A higher incidence of ONJ (8.1%) was noted in our sample (n = 183). Dental intervention after zoledronic acid (ZA) administration showed a statistical significance (P < 0.001). No significance (P value) was noted with respect to sex (0.78), age (0.28), median duration (0.9), and median dosage (0.9) of ZA. CONCLUSION: Oro-dental screening and dental monitoring shall reduce the incidence of ONJ. Within the limitations of our study, no significant relation could be pointed toward the dosage and duration of the drug and development of ONJ. |
format | Online Article Text |
id | pubmed-5863406 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Medknow Publications & Media Pvt Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-58634062018-03-29 Osteonecrosis of the Jaw among Patients Receiving Antiresorptive Medication: A 4-year Retrospective Study at a Tertiary Cancer Center, Kerala, India Sankar, Pramod S Thilak, SA Nayak, P Tripathy, JP Satheesan, B Rajitha, AV Contemp Clin Dent Original Article PURPOSE: Osteonecrosis of the jaw (ONJ) is a rare but complicated side effect of antiresorptive medications. The aim of the study is to evaluate the dental and drug-related factors related to ONJ among patients on these drugs at a tertiary cancer center, India. METHODOLOGY: A retrospective record review of patients who received antiresorptive medication at our center from 2011 to 2014 was done. The demographic factors, type, dosage, and duration of the medication and dental history were collected, and the data were entered an analyzed using Epidata software. RESULTS: A higher incidence of ONJ (8.1%) was noted in our sample (n = 183). Dental intervention after zoledronic acid (ZA) administration showed a statistical significance (P < 0.001). No significance (P value) was noted with respect to sex (0.78), age (0.28), median duration (0.9), and median dosage (0.9) of ZA. CONCLUSION: Oro-dental screening and dental monitoring shall reduce the incidence of ONJ. Within the limitations of our study, no significant relation could be pointed toward the dosage and duration of the drug and development of ONJ. Medknow Publications & Media Pvt Ltd 2018 /pmc/articles/PMC5863406/ /pubmed/29599581 http://dx.doi.org/10.4103/ccd.ccd_696_17 Text en Copyright: © 2018 Contemporary Clinical Dentistry http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms. |
spellingShingle | Original Article Sankar, Pramod S Thilak, SA Nayak, P Tripathy, JP Satheesan, B Rajitha, AV Osteonecrosis of the Jaw among Patients Receiving Antiresorptive Medication: A 4-year Retrospective Study at a Tertiary Cancer Center, Kerala, India |
title | Osteonecrosis of the Jaw among Patients Receiving Antiresorptive Medication: A 4-year Retrospective Study at a Tertiary Cancer Center, Kerala, India |
title_full | Osteonecrosis of the Jaw among Patients Receiving Antiresorptive Medication: A 4-year Retrospective Study at a Tertiary Cancer Center, Kerala, India |
title_fullStr | Osteonecrosis of the Jaw among Patients Receiving Antiresorptive Medication: A 4-year Retrospective Study at a Tertiary Cancer Center, Kerala, India |
title_full_unstemmed | Osteonecrosis of the Jaw among Patients Receiving Antiresorptive Medication: A 4-year Retrospective Study at a Tertiary Cancer Center, Kerala, India |
title_short | Osteonecrosis of the Jaw among Patients Receiving Antiresorptive Medication: A 4-year Retrospective Study at a Tertiary Cancer Center, Kerala, India |
title_sort | osteonecrosis of the jaw among patients receiving antiresorptive medication: a 4-year retrospective study at a tertiary cancer center, kerala, india |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5863406/ https://www.ncbi.nlm.nih.gov/pubmed/29599581 http://dx.doi.org/10.4103/ccd.ccd_696_17 |
work_keys_str_mv | AT sankarpramods osteonecrosisofthejawamongpatientsreceivingantiresorptivemedicationa4yearretrospectivestudyatatertiarycancercenterkeralaindia AT thilaksa osteonecrosisofthejawamongpatientsreceivingantiresorptivemedicationa4yearretrospectivestudyatatertiarycancercenterkeralaindia AT nayakp osteonecrosisofthejawamongpatientsreceivingantiresorptivemedicationa4yearretrospectivestudyatatertiarycancercenterkeralaindia AT tripathyjp osteonecrosisofthejawamongpatientsreceivingantiresorptivemedicationa4yearretrospectivestudyatatertiarycancercenterkeralaindia AT satheesanb osteonecrosisofthejawamongpatientsreceivingantiresorptivemedicationa4yearretrospectivestudyatatertiarycancercenterkeralaindia AT rajithaav osteonecrosisofthejawamongpatientsreceivingantiresorptivemedicationa4yearretrospectivestudyatatertiarycancercenterkeralaindia |